This panel analyses 72 genes associated with the reported increased risk in at least one study of one or more of the following hereditary cancers: breast, colorectal, endometrial, gastric, melanoma, ovarian, pancreatic, prostate, renal, skin, thyroid, and uterine. The test can be used to confirm the presence of a genetic variant in already diagnosed cancer… Read more »
Kit Category: Cancer
Genetic risk test associated with hereditary common cancers This test provides a comprehensive analysis of an individual’s genetic risk of developing common hereditary cancers. It analyses 84 genes associated with hereditary cancers across 8 major organ systems. It is designed for individuals who have a personal or family history of mixed cancers affecting multiple organ… Read more »
Genetic risk test associated with colorectal cancer This test analyses 20 genes that are associated with colorectal cancer, and the option of a further 10 genes that have preliminary evidence of an association with this cancer type. It is designed for early detection to help guide the right treatment, reduce the risk of recurrence and… Read more »
Genetic risk test associated with prostate cancer This test analyses 19 genes that are associated with increased hereditary risk of developing prostate cancer. It is designed to identify early detection and help guide the right treatment pathway, reduce the risk of reoccurrence and increase the chances of survival. It is suitable for men who have… Read more »
Genetic testing to help guide breast cancer treatment This test analyses 12 genes known to significantly increase the risk of developing breast and ovarian cancer as a second primary. It identifies genetic variants in the BRCA1 and BRCA2 genes which are associated with Hereditary Breast and Ovarian Cancer syndrome, along with a further 10 established… Read more »
Personalise your patient’s cancer care with molecular testing Caris MI Tumor Seek™ is a comprehensive molecular profiling service that reveals the unique characteristics of a patient’s cancer to help guide more precise and personalised treatment choices. Using advanced molecular profiling and Next Generation Sequencing (NGS) the DNA and RNA of the tumour are precisely analysed… Read more »
If you have already been diagnosed with cancer, this test is a rapid analysis that can help you make vital decisions about your treatment – particularly if you are considering surgical options.
All of us have a 1 in 2 lifetime risk of cancer, but some common cancers – breast, melanoma, pancreatic, prostate and ovarian – are known to occur more frequently in families, passing from one generation to the next. It’s because certain gene mutations can be inherited – particularly those in BRCA1 and BRCA2 genes – and this test focuses on these, pus another six genes which can indicate additional risk.
The Prosigna® Breast Cancer Prognostic Gene Signature Assay Prosigna® is a second-generation prognostic test that comprehensively informs treatment decisions in breast cancer patients. The Prosigna® risk of recurrence score adds significant prognostic information to conventional risk factors, including pathological analysis of the patient tumour, and protein markers detected using Immunohistochemistry. It is used by healthcare… Read more »
If you have been diagnosed with the blood cancer, multiple myeloma, this test can help your clinician select the best treatment for you.